May 26, 2018 1:30 PM ET


Company Overview of Abdi Ibrahim Ilaç Sanayi ve Ticaret A.S.

Company Overview

Abdi Ibrahim Ilaç Sanayi ve Ticaret A.S. manufactures and markets pharmaceuticals for customers in Turkey and internationally. It offers antianemic, antibacterial/antiviral, gastrointestinal, nervous system, ophthalmic, and urogenital system drugs; vitamins and minerals; CANMAb, a biosimilar of trastuzumab used for the treatment of Her2+ breast cancer; and respiratory system, cardiovascular system, dermatologic, endocrine and metabolism, and NSAI and myorelaxant products. Abdi Ibrahim Ilaç Sanayi ve Ticaret A.S. was formerly known as Ibrahim Abdi Barut and changed its name to Abdi Ibrahim Ilaç Sanayi ve Ticaret A.S. in 1975. The company was founded in 1912 and is based in Istanbul, Turkey. I...

Resitpasa Mahallesi

Eski Büyükdere Caddesi No: 4



Istanbul,  34467


Founded in 1912


90 212 366 84 00


90 212 276 20 20

Key Executives for Abdi Ibrahim Ilaç Sanayi ve Ticaret A.S.

Chief Executive Officer and Member of The Board of Directors
Chief Financial Officer
General Manager of Technical
Director of Corporate Communications
Compensation as of Fiscal Year 2017.

Abdi Ibrahim Ilaç Sanayi ve Ticaret A.S. Key Developments

Abdi Ibrahim Remede Pharma Obtains U.S. Food and Drug Administration Approval for Biosimilar Trastuzumab

Abdi Ibrahim Remede Pharma (AIRP) is Biocon's partner in Algeriafor the registration, marketing and pharmacovigilance monitoring of multiple Biotech Products. In 2016, AIRP launched the first Biosimilar of Trastuzumab (CANMAb®) in Algeria for the treatment of Her2+ breast cancer. Biocon's trastuzumab (filed and marketed through its US partner) is now approved by US FDA. Biocon's trastuzumab is the first FDA-approved biosimilar trastuzumab and the first biosimilar from Biocon´s portfolio to be approved in the U.S. It is only the second oncology biosimilar approved by US FDA. It received FDA approval after a 16-0 favorable vote by the Oncology Drugs Advisory Committee (ODAC), consisting of oncologists, pharmacologists, statisticians, manufacturing and other experts. In addition, the European Medicines Agency (EMA) has accepted the Marketing Authorization Application for Biocon's proposed biosimilar trastuzumab for review.

Abdi Ibrahim Seeks Acquisitions

Abdi Ibrahim Ilaç Sanayi ve Ticaret A.S. is seeking acquisitions. Nezih Barut, Chairman of Abdi Ibrahim, said, "We continue relentlessly our overseas investments, which stand at the heart of our growth targets. Our Kazakhstan factory started production in 2015. In 2017, Abdi Ibrahim Remede Pharma in Algeria will become operational, as our third manufacturing facility besides Turkey and Kazakhstan. In line with our 2020 goals, we have designated our five areas of growth as current products, new products, international markets operations, contract manufacturing services, and seizing merger and acquisition opportunities; and will continue to make swift progress in each of these areas."

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Abdi Ibrahim Ilaç Sanayi ve Ticaret A.S., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at